What is a stock summary page? Click here for an overview.
Business Description
Scilex Holding Co
NAICS : 325411
SIC : 2834
ISIN : US80880W1062
Description
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.09 | |||||
| Equity-to-Asset | -2.07 | |||||
| Debt-to-Equity | -0.2 | |||||
| Debt-to-EBITDA | -0.57 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -13.09 | |||||
| Beneish M-Score | -8.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.5 | |||||
| 3-Year EBITDA Growth Rate | -13.9 | |||||
| 3-Year EPS without NRI Growth Rate | -10.8 | |||||
| 3-Year Book Growth Rate | 14.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 93.47 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.7 | |||||
| 9-Day RSI | 53.01 | |||||
| 14-Day RSI | 48.24 | |||||
| 3-1 Month Momentum % | -38.56 | |||||
| 6-1 Month Momentum % | -65.92 | |||||
| 12-1 Month Momentum % | -81.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.16 | |||||
| Quick Ratio | 0.15 | |||||
| Cash Ratio | 0.01 | |||||
| Days Inventory | 68.29 | |||||
| Days Sales Outstanding | 206.83 | |||||
| Days Payable | 966.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.3 | |||||
| Shareholder Yield % | -106.96 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.51 | |||||
| Operating Margin % | -163.96 | |||||
| Net Margin % | -128.66 | |||||
| FCF Margin % | 33.13 | |||||
| ROA % | -74.22 | |||||
| ROIC % | -68.18 | |||||
| 3-Year ROIIC % | 265.74 | |||||
| ROC (Joel Greenblatt) % | -2149.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 0.87 | |||||
| PS Ratio | 0.63 | |||||
| Price-to-Free-Cash-Flow | 1.65 | |||||
| Price-to-Operating-Cash-Flow | 1.63 | |||||
| EV-to-EBIT | -1.22 | |||||
| EV-to-Forward-EBIT | -5.87 | |||||
| EV-to-EBITDA | -1.29 | |||||
| EV-to-Revenue | 1.53 | |||||
| EV-to-Forward-Revenue | 1.06 | |||||
| EV-to-FCF | 4.76 | |||||
| Earnings Yield (Greenblatt) % | -81.97 | |||||
| FCF Yield % | 38.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SCLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scilex Holding Co Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 56.59 | ||
| EPS (TTM) ($) | -0.63 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 121.86 | ||
| 14-Day RSI | 48.24 | ||
| 14-Day ATR ($) | 0.039572 | ||
| 20-Day SMA ($) | 0.28585 | ||
| 12-1 Month Momentum % | -81.08 | ||
| 52-Week Range ($) | 0.21 - 2.3 | ||
| Shares Outstanding (Mil) | 183.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scilex Holding Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scilex Holding Co Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Scilex Holding Co Frequently Asked Questions
What is Scilex Holding Co(SCLX)'s stock price today?
The current price of SCLX is $0.26. The 52 week high of SCLX is $2.30 and 52 week low is $0.21.
When is next earnings date of Scilex Holding Co(SCLX)?
The next earnings date of Scilex Holding Co(SCLX) is 2025-05-13 Est..
Does Scilex Holding Co(SCLX) pay dividends? If so, how much?
Scilex Holding Co(SCLX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers